Methods of using rebastinib in the treatment of disorders
AssigneeDeciphera Pharmaceuticals, LLC
InventorsRodrigo Ruiz Soto, Keisuke Kuida, Haroun Achour
Life of this patent
Estimating the term…
Abstract
Described herein are methods of treating various disorders in patients in need thereof, comprising administering to the patient the compound of Formula (I) or a pharmaceutically acceptable salt thereof. Exemplary disorders that can be treated by the methods described herein include gynecologic carcinosarcomas, endometrial adenocarcinomas, mesotheliomas, ovarian cancers, pancreatic ductal adenocarcinomas, and lung cancers.
Claims125
A method of treating a gynecologic carcinosarcoma in a patient that has previously received at least one line of treatment for the gynecologic carcinosarcoma, and is in need thereof, comprising administering to the patient an effective amount of the compound of Formula (I):
- or a pharmaceutically acceptable salt thereof.
A method of treating a gynecologic carcinosarcoma in a patient that has previously received at least one line of treatment for the gynecologic carcinosarcoma, and is in need thereof, comprising administering to the patient an effective amount of:
- a) the compound of Formula (I)
- or a pharmaceutically acceptable salt thereof;
- and
- b) paclitaxel.
A method of treating endometrial adenocarcinoma in a patient in need thereof, comprising administering to the patient an effective amount of the compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
A method for achieving at least a partial response in a patient having endometrial adenocarcinoma, comprising administering to the patient an effective amount of the compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
A method for achieving a stable disease condition in a patient having endometrial adenocarcinoma, comprising administering to the patient an effective amount of the compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
A method of treating mesothelioma in a patient in need thereof, comprising administering to the patient about 50 mg to about 200 mg of the compound of Formula (I)
- or a pharmaceutically acceptable salt thereof per day.
A method for achieving at least a partial response in a patient having mesothelioma, comprising administering to the patient an effective amount of the compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
A method for achieving a stable disease condition in a patient having mesothelioma, comprising administering to the patient the compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
A method of treating ovarian cancer in a patient in need thereof, comprising administering to the patient 50 mg, twice per day, of a compound of Formula (I):
- and 80 mg/m2 of paclitaxel once per week.
A method of treating ovarian cancer in a patient in need thereof, comprising administering to the patient 100 mg, twice per day, of a compound of Formula (I):
- and 80 mg/m2 of paclitaxel once per week.
A method of treating pancreatic ductal adenocarcinoma in a patient in need thereof, comprising administering to the patient an effective amount of a compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
A method for achieving at least a partial response in a patient having pancreatic ductal adenocarcinoma, comprising administering to the patient an effective amount of the compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
A method for achieving a stable disease condition in a patient having pancreatic ductal adenocarcinoma, comprising administering to the patient an effective amount of the compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
A method of treating lung cancer in a patient in need thereof, comprising administering to the patient an effective amount of a compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
A method for achieving at least a partial response in a patient having lung cancer, comprising administering to the patient an effective amount of the compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
A method for achieving a stable disease condition in a patient having lung cancer, comprising administering to the patient an effective amount of the compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.